4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
June 24, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH)Complement factor...
4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
June 18, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
24-week landmark safety and clinical activity data for 45 patients enrolled in the Population Extension cohort expected to be presented (N=30 at 3E10 vg/eye)Clinical data will be presented by Raj K....
4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
June 08, 2024 16:30 ET
|
4D Molecular Therapeutics, Inc.
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher...
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
June 06, 2024 07:30 ET
|
4D Molecular Therapeutics, Inc.
Clinically meaningful improvements in ppFEV1 at 12 months observed in 2 of 3 participants with mild to moderate baseline lung function impairment (ppFEV1 50-80%) and >6 months follow up ...
4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
June 04, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT to Participate in Upcoming Investor Conferences
June 03, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
May 30, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
Interim clinical data will be presented by Jennifer L. Taylor-Cousar, M.D., Principal Investigator of the AEROW clinical trial at the 47th European Cystic Fibrosis Conference on Thursday, June 6, 2024...
4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
May 09, 2024 16:05 ET
|
4D Molecular Therapeutics, Inc.
Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients with severe disease activity and high treatment burden enabling advancement into Phase 3...
4DMT to Participate in Upcoming Investor Conference
May 07, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
EMERYVILLE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full...
4DMT Announces Presentations at ARVO 2024 Annual Meeting
May 01, 2024 08:00 ET
|
4D Molecular Therapeutics, Inc.
Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a...